Prevacid's decline drags down Takeda
This article was originally published in Scrip
Sharply lower US sales of Prevacid (lansoprazole) following the loss of exclusivity, together with the strength of the yen, both hurt Takeda in the nine months to 31 December, when net sales at Japan's largest pharma company slid by 4% to ¥1,081.1 billion ($13.26 billion).
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.